Emblem Cannabis Corp. is Ready for IPO
The Future of the Cannabis Market
The market for legal marijuana is without a doubt on a prosperous path.
For starters, we’re finally seeing movement towards legalizing marijuana use in the U.S. More states are starting to realize the benefits that marijuana can (and will) have on the economy.
Currently the main priority is directed towards legalizing medical marijuana use, but that hasn’t stopped some states from taking the leap towards legalizing marijuana for recreational use.
During the election in November 2016, four states (California, Nevada, Massachusetts, and Maine) voted for legal recreational use and sales. In addition to those four states, Alaska, Washington, Oregon, and D.C. have already legalized recreational use.
According to an analysis from Marijuana Policy Group, the marijuana industry created more than 18,000 full-time jobs last year and generated $2.39 billion in economic activity in Colorado.
ArcView Market Research is predicting that the legal cannabis market will see $21.8 billion in total annual sales by 2020. ArcView expects the market to see an annual growth rate of 30% in the next few years.
ArcView CEO Troy Dayton said:
I think that we are going to see in 2016 this next wave of investors, the next wave of business operators, and people who’ve sort of been watching or dipping their toe in, really starting to swing for the fences and take it really seriously.
While marijuana remains illegal on the federal level in the United States, the Canadian government has made medical marijuana use legal in all of its provinces.
Business with Emblem
Emblem Cannabis Corporation is a fully integrated medical marijuana, health care, and cannabinoid-based pharmaceutical company. It's licensed by the Government of Canada, which allows it to produce medical cannabis.
The company is based in Paris, Ontario, and as of right now it's officially open for business. It has the ability to reach patients across the country. All they need to do is register and fulfill orders via Emblem’s website, emblemcannabis.com — of course, as long as those patients have a signed medical document.
According to a press release from Emblem on November 22, 2016, in less than a year, the number of medical marijuana patients in Canada has more than doubled — 91,000 Canadians are registered.
Right now the market is seeing a saturation of mid-grade products for customers... and that's where Emblem stands out. It's offering premium products at decent prices.
Having quality products will give Emblem the highest advantage over the Canadian medical marijuana market.
Maxim Zavet, president of Emblem, said this in a recent press release:
A growing number of Canadians, including doctors, are beginning to discover the amazing and natural therapeutic benefits of cannabis...
At Emblem, we are a group of dedicated growers and inspired enthusiasts committed to growing premium cannabis because we passionately believe in its healing powers.
Emblem has constructed its business into three divisions: Production, Pharmaceutical, and Cannabis Education. Breaking up its business into these three divisions allows for each division to focus on what they do best.
Additionally, the company is devoted to its customers and maintaining open communication with them, so any questions they might have will be immediately answered.
Emblem wants to keep its consumers educated while also helping them choose the best product for their medical condition(s).
One of the most promising aspects of this company — besides the fact that it's in a lucrative market — is that its founders and management team have an extremely successful track record.
They know what they’re doing.
John Stewart, who leads Emblem’s pharmaceutical division, is the former CEO of Purdue Pharma Canada and Purdue Pharma U.S.
Purdue Pharma is one of the largest privately held pharmaceutical companies in the world.
While working for Purdue Pharma, Stewart was responsible for launching 11 new products including OxyContin, a $2 billion a year drug.
Stewart’s success at Purdue Pharma proves that he has the insight and business expertise to lead Emblem into a successful future.
Emblem has the potential to be the biggest legal cannabis IPO of the year.
Emblem is expected to go public on the TSX-V under the ticker symbol “EMC” today (11/30) or Thursday (12/1). The IPO price is likely to be between $1 and $1.25 per share.
It's already sold out of its pre-IPO offerings — its last round was priced at $1.15 CAD. It's also planning on a U.S. listing shortly following the Canadian listing, but details of that are still unclear.
Emblem’s management invested $6 million of their own money into the business plan to create the company that Emblem is today... a company that has an outstanding production facility that's able to produce high-quality products — a huge reason it already has 1,000 shareholders.
If you'd like further details on Emblem's IPO, sign up directly with the company to be on its public announcement list by emailing email@example.com.
Until next time,